The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody.
about
HIV broadly neutralizing antibody targetsGlobal shape and ligand binding efficiency of the HIV-1-neutralizing antibodies differ from those of antibodies that cannot neutralize HIV-1Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodiesEmergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypesComprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer.HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single InfectionIncomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal AntibodiesA New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo.Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses.Dose-response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodiesGlycan-Dependent Neutralizing Antibodies Are Frequently Elicited in Individuals Chronically Infected with HIV-1 Clade B or C.CD4 binding site broadly neutralizing antibody selection of HIV-1 escape mutants.Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site.Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.Germline-targeting immunogens.Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response.Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.Neutralization function affected by single amino acid replacement in the HIV-1 antibody targets.Time-course, negative-stain electron microscopy-based analysis for investigating protein-protein interactions at the single-molecule level.Identification of a novel HIV-1-neutralizing antibody from a CRF07_BC-infected Chinese donor.Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses.Designation of fingerprint glycopeptides for targeted glycoproteomic analysis of serum haptoglobin: insights into gastric cancer biomarker discovery.Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models.Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.Production of complex viral glycoproteins in plants as vaccine immunogensDiverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies
P2860
Q27026662-D79942D6-2260-4646-9B5A-65FDAA76D678Q28250040-BD149836-AC38-45C7-8AD3-7C80184983CBQ34392963-2943F714-6EBA-4A88-88FD-63CEBCB06206Q34594701-9215B4E0-3474-4DD2-A11A-C64422C397EDQ35034268-F52AF0BA-F8EE-4329-B3FC-E4BB04CB3E23Q35217426-C7440543-22FE-4C9F-9658-8981337B5F03Q35640998-9EDC7DE9-9870-4CBA-991A-296090F356A0Q35686970-7A98E612-D2C6-4C30-8733-BDDF8DEFDEBFQ35743897-4D6315AD-B49D-4A66-A18F-B75846489B1FQ35827024-31323035-550E-4F49-A9F4-F33C41B8634EQ36053810-96CED083-3C6F-421C-8EC5-307ABC75F33EQ36105672-F063A696-0272-4B9D-B501-9028966B38E0Q36294701-A3F81CF6-F0A9-494B-8F52-16BA86050693Q36810796-7B6AFBAE-2BBF-48D5-B9BE-43A88D83A6D9Q37409244-16407EFD-AA00-46B8-8B8D-9F13AD509766Q38645979-688226AD-0CE2-472C-83AF-B59982911C4DQ38764547-F85E0DA3-CA2F-4AF6-8C18-E83747E3D8DFQ40043429-9DCCC462-D09D-4FE1-8280-6610B46B00CFQ40679052-693B711C-8EAF-4A17-B99E-DC218B920961Q41922279-B819B9D8-D110-429E-958B-916E8FFAD2D9Q41925648-DC806D1C-06F3-4302-B8B0-F90416F046C5Q42362648-AB8528D9-0CD1-4D7E-B7C5-FD736BF5B17CQ46202850-2735D95E-6D1F-4BF1-8623-F7E2BFA34056Q47213195-E0AC32BD-E56F-41ED-978B-93D274B39659Q47215738-45578369-7DBB-4DA7-A8C8-3617F60841A3Q53689028-5B94FC81-EFEC-42DA-B2E7-87B53CDD34BDQ56398263-99FB0F7F-D4B4-43E5-93C0-34CDEF163C75Q57003103-D4E7C151-C3B3-40DA-8EE8-C4BDEC41559F
P2860
The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The N276 glycosylation site is ...... ific HJ16 monoclonal antibody.
@ast
The N276 glycosylation site is ...... ific HJ16 monoclonal antibody.
@en
The N276 glycosylation site is ...... ific HJ16 monoclonal antibody.
@nl
type
label
The N276 glycosylation site is ...... ific HJ16 monoclonal antibody.
@ast
The N276 glycosylation site is ...... ific HJ16 monoclonal antibody.
@en
The N276 glycosylation site is ...... ific HJ16 monoclonal antibody.
@nl
prefLabel
The N276 glycosylation site is ...... ific HJ16 monoclonal antibody.
@ast
The N276 glycosylation site is ...... ific HJ16 monoclonal antibody.
@en
The N276 glycosylation site is ...... ific HJ16 monoclonal antibody.
@nl
P2093
P2860
P1433
P1476
The N276 glycosylation site is ...... ific HJ16 monoclonal antibody.
@en
P2093
David Davis
Davide Corti
Elisabeth Willems
Guido Vanham
Katleen Vereecken
Leo Heyndrickx
Sunita S Balla-Jhagjhoorsingh
P2860
P304
P356
10.1371/JOURNAL.PONE.0068863
P407
P577
2013-07-17T00:00:00Z